PBAC's latest decision on Atomoxetine hydrochloride: Recommended with restriction (2008). Considered for treatment of attention deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
5
first 2005
Submissions
5
2005 → 2008
Eligible population
patients with attention deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, by a paediatrician or psychiatrist according to the DSM-IV criteria
Therapy area
Neurology
Evidence base
RCT
Economic model
Not modelled
ICER note
No economic evaluation was presented in the submission
ICER (historical)
$15k/QALY–$45k/QALY across 3 submissions (2005–2006) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Nov 2005: Not recommended · Authority Required — ICER $45k/QALY
Jul 2006: Not recommended · Authority Required — ICER $75k/QALY
Nov 2006: Recommended with restriction · Authority Required — ICER $45k/QALY
Jul 2008: Recommended with restriction · Authority required
Jul 2008: Recommended with restriction · Authority Required